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Background: Viral hepatitis is a serious public health problem affecting billions of people globally. Limited
information is available on this issue in Morocco. This cross-sectional study was undertaken with the aim of
determining the seroprevalence and risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV) among the
general population and among blood donors.
Methods: Blood samples from volunteers, have been screened with ELISA tests for detecting the hepatitis-B surface
antigen (HBsAg) and anti-HCV. Within the seroreactive patients for HCV in the general population, RT-PCR was
performed by the Cobas Ampliprep/Cobas Amplicor.
Results: HCV and HBV-seropositivity was documented in 1.58% and 1.81% out of 41269 and 23578 participants
respectively from the general population. Two patients were found to be co-infected. HCV-RNA was detected by
PCR in 70.9% of the 195 anti-HCV positive subjects. The anti-HCV prevalence was not different among males and
females (P = 0.3). It increased with age; the highest prevalence was observed among subjects with >50 years old
(3.12%). Various risk factors for acquiring HCV infection were identified; age, dental treatment, use of glass syringes
and surgical history. In addition to these factors, gender and sexual risk behaviors were found to be associated with
higher prevalence of hepatitis B. The HBV positivity was significantly higher among males than females participants
in all age groups (P < 0.01). The peak was noticed among males aged 30–49 years (2.4%). None of the 152 persons
younger than 20 years had HBsAg or anti-HCV. The prevalence of anti-HCV and HBsAg among 169605 blood
donors was 0.62% and 0.96% respectively.
Conclusions: Our study provided much important information concerning hepatitis B and C prevalence and risk
factors; it confirmed the intermediate endemicity for HCV infection and pointed to a decreasing trend of HBV
incidence, which might reclassify Morocco in low HBV endemicity area. This could be attributed primarily to the
universal HBV vaccination among infants and healthcare workers over the past 13 years. HCV and HBV infections in
the present survey were mainly associated with nosocomial exposures. Prevention and control of HBV infection are
needed to reduce HBV transmission between adults.
Keywords: Hepatitis B, Hepatitis C, Prevalence, General population, Risk factors, Blood donors, Morocco* Correspondence: abdelouaheb.bennani@pasteur.ma
1Molecular Biology Laboratory, Department of Medical Biology, Pasteur
Institute of Morocco, 1, Place Louis Pasteur, 20360, Casablanca, Morocco
Full list of author information is available at the end of the article
© 2013 Baha et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Baha et al. BMC Public Health 2013, 13:50 Page 2 of 8
http://www.biomedcentral.com/1471-2458/13/50Background
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are
among the principal causes of severe liver disease, includ-
ing hepatocellular carcinoma (HCC) and cirrhosis-related
end-stage liver disease. The World Health Organization
(WHO) has estimated that there are 360 million chronic-
ally HBV infected people and 5.7 million HBV-related
cases worldwide [1]. HBV is highly infectious and trans-
mitted mainly via blood, body-fluid contact, and vertical
transmission [2]. The hepatitis B surface antigen (HBsAg)
in serum is the first seromarker to indicate active HBV in-
fection, either acute or chronic [3]. A hepatitis B vaccine,
available since 1982, has a high efficacy in the prevention
of HBV transmission [2] and has brought about remark-
able changes in the global epidemiology of HBV infection.
HCV infection is also common worldwide. It is transmit-
ted in a manner similar to HBV and it is estimated that
about 3% of the world’s population carry HCV, with 3 to 4
million new infections per year [4]. Hepatitis C is generally
asymptomatic, with a strong tendency (up to 80%) for pro-
gression to persistent infection [5]. Chronic HCV infection
progresses at a variable rate to cirrhosis in 15 to 20% of
patients, who then have a 1 to 4% annual risk of develop-
ing hepatocellular carcinoma in 20–30 years [6].
Morocco has been placed by the WHO into the inter-
mediate zone of prevalence for both hepatitis B and C;
however the exact number of persons infected is un-
known for the reason that no large-scale epidemic data
exist to assess the true HCV and HBV infection burden
in Morocco. Although a few studies have been carried
out, they were affected by a selection bias because most
studies are generally based on subjects from risk groups
or blood donors with lacking information on children
and senior citizens not generally included in as specia-
lized groups [7-9].
The scarcity of data and the degree to which they are
out of date were the main reasons behind a nationwide
cross-sectional survey aimed to determine the preva-
lence and risk factors of HCV and HBV infections in the
general population and among blood donors to unravel
the true status of viral hepatitis in apparently healthy
Moroccan persons and thus provide valuable informa-
tion about surveillance and estimation.
Methods
Study design, setting and population
General population
This was a nationwide cross-sectional survey enrolling in
the large screening program for hepatitis B and C con-
ducted by the Pasteur Institute of Morocco and carried
out in eleven major Moroccan regions between December
2005 and June 2011. The target subjects in this study were
the apparently healthy Moroccan individuals which were
selected to be as representative of the demographiccharacteristics as possible in regarding areas of Morocco.
To construct the national probability sample, a stratified,
random cluster sampling method was used to select the
study population. In the first stage, names of private and
public organizations (companies, agencies, banks, factor-
ies, schools. . .) from different prefectures and provinces of
regions were obtained using directories. Lists were com-
piled using excel tool to select 288 organisms. To invite
the selected structures to participate in the survey, a letter
was sent with standardized information regarding the
study. Each organism has agreed to participate provided a
list of the active or retired personnel (also students in case
of schools). The study population was selected by a sys-
tematic 1:3 sampling procedure; every third person from
each list was selected and approached for participation.
The study was also open for all persons who wish to
participate.
The investigative team performing the fieldwork con-
sisted of physicians who performed clinical examination,
paramedics who collected blood samples, and trained so-
cial workers who explain the objectives of the study and
interview each participant. No willful participation was
allowed and if any eligible candidate declined to partici-
pate, his or her name was dropped from the list of parti-
cipants. An informed consent was obtained from the
participating subjects and, in the case of the minors, the
parents or tutors. A standard and individual question-
naire was used to gather data related to demographic
and socio-economic characteristics, age, gender, present
and past health status, history of jaundice, and possible
risk factors for transmitting viral hepatitis.
In the end, 280 structures (97.3%) and 41 269 out of 41
311 participants (99.9%) agreed to participate in the sur-
vey. The first 17 691 persons recruited were tested only
for anti-HCV Ab and the subsequent 23 578 persons were
tested for both anti-HCV and HBsAg. All subjects were
grouped by sex and age range. The collected blood was
transferred to the Molecular Biology Laboratory at Pasteur
Institute of Morocco under sterile conditions in ice bags,
separated and stored at −70°C until laboratory testing was
performed.
The HBsAg and the IgG antibodies to HCV markers
were serologically assessed using a third generation enzyme
immunoassay (Murex HBsAg Version 3, Abbott-Murex,
South Africa) and (Murex, anti-HCV version 4.0 Abbott
Kyalami, South Africa) respectively. Positive samples were
retested for confirmation using an automated microparticle
enzyme immunoassay (Abbott, AxSYM. System, Wiesbaden,
Germany).
Anti-HCV–positive subjects were recalled for further
evaluation at a subsequent date. A detailed clinical
examination was performed and blood samples were fur-
ther assessed for HCV RNA by polymerase chain reac-
tion using the Cobas Ampliprep/Cobas Amplicor HCV
Figure 1 Serological features of anti-HCV prevalence in
Morocco. Bars represent the number of subjects in each group
indicated by left vertical axis, and the points represent the
prevalence in each group indicated by right vertical axis. The
horizontal axis represents the age ranges. A, Overall characterization
of anti-HCV by age group. B, Overall characterization of anti-HCV by
gender, M, male, F, female.
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Blood donors
The participants in this cross-sectional study were all vo-
lunteer blood donors who donated blood at the Casa-
blanca Regional Blood Transfusion Center between
January 1st, 2008 and December 31, 2010.
The donors were interviewed by physicians before do-
nation; each donor was requested to fill a blood donor’s
form and was obliged to satisfy the center’s criteria: age
over 18 and less than 65, body weight over 50 kg, nor-
mal body temperature, absence of clinical signs of an
acute infective response, no history of infectious and
chronic diseases and information about any high-risk be-
havior. Therefore all participants selected in this study
are presumed without a history of known or obvious risk
factor. Care was also taken to make sure that no donor
was used more than once in this study. Unsuitable
donors were excluded.
All blood samples were routinely screened for
transfusion-transmitted diseases (HBV, HCV, HIV and
Syphilis) according to established screening procedures
and tests; hence specimens were tested for HBsAg and
anti-HCV antibodies by Murex HBsAg Version 3 and
Murex Ag/Ab HCV Combination Assay (Abbott-Murex,
South Africa) respectively. Reactive samples were retested
in duplicate. Repeatedly reactive samples were confirmed
by means of recombinant immunoblot assay for HCV
(RIBA, Innogenetics). Samples were considered to be posi-
tive if were reactive for both tests.
All procedures were followed in accordance with the
current revision of the declaration of Helsinki, approved
by the ethical committee of Pasteur Institute of Morocco.
Statistical analysis
Statistical analyses were performed by using SPSS 16.0
software. The overall prevalence of HCV and HBV markers
was expressed as the percentage of seropositive samples.
The prevalence odds ratios (OR) and Confidence intervals
(CI) of 95% for OR estimates were also estimated. A level
of p < 0.05 was used to indicate statistical significance.
Results
General population
In all, 41 269 (sex-ratio (M/F) = 2.30) serum samples were
tested for anti-HCV Ab analysis and 23 578 (sex-ratio
(M/F) = 1.84) subjects were enrolled for HBsAg detection.
The overall mean age was 45 (± 10.9) years, ranging from
5 to 84 years.
The seroprevalence of anti-HCV Ab was found to be
1.58%, corresponding to 651 seropositive patients out of
41 269 participants, of those individuals, viral RNA was
detected in 70.9%. The prevalence of anti-HCV in the<20, [20–29], [30–39], [40–49] and >50 age groups was
0%, 0.77%, 0.92%, 1.17% and 3.12%, respectively. For
those subjects, the anti-HCV prevalence increased with
age (Figure 1A).
The overall prevalence of anti-HCV in 12 497 female
subjects was 1.48% (185 positive), which was lower than
that in the 28 772 male subjects, 1.62% (466 positive).
For those subjects younger than 30 years, the prevalence
of anti-HCV in females was lower than that in males,
then it increased and became higher than that in males
in >30 age groups (Figure 1B).
The overall prevalence of HBsAg was 1.81% (426 posi-
tive) in 23578 subjects. HBsAg prevalence in <20, [20–29],
[30–39], [40–49] and >50 age groups was 0%, 1.41%,
2.12%, 1.95% and 1.71%, respectively, as well as it showed
an increase with age from 1.41% in [20–29] group to
2.12% and 1.95% in [30–39] and [40–49] group respect-
ively, then decrease in the older group >50 years old to
1.71% (Figure 2A).
Figure 2 Serological features of HBsAg prevalence in Morocco.
Bars represent the number of subjects in each group indicated by
left vertical axis, and the points represent the prevalence in each
group indicated by right vertical axis. The horizontal axis represents
the age ranges. A, Overall characterization of HBsAg by age group.
B, Overall characterization of HBsAg by gender, M, male, F, female.
Table 1 Distribution of Hepatitis C virus serological marker








N % N %
Age
<40 144 0.9 16 686 99.1 2.5 (2.0-2.9) <0.01
>40 507 2.1 23 932 97.9
Sex
Female 185 1.5 12 312 98.5 0.9 (0.8-1.0) 0.3
Male 466 1.6 28 306 98.4
Dental therapy
No 244 0.8 28 351 99.2 3.8 (3.3- 4.5) <0.01
Yes 407 3.2 12 267 96.8
Use of glass syringes
No 329 1.2 27 905 98.8 2.1 (1.8- 2.5) <0.01
Yes 322 2.5 12 713 97.5
Surgical history
No 403 1.4 28 027 98.6 1.37 (1.2-1.6) 0.01
Yes 248 1.9 12 591 98.1
Blood transfusion
No 546 1.6 34 566 98.4 1.1 (0.9-1.4) 0.4
Yes 105 1.7 6052 98.3
Piercing/tattoo
No 599 1.6 37 694 98.4 1.1 (0.8-1.5) 0.5
Yes 52 1.7 2924 98.3
Multiple Sexual
partners
No 634 1.6 39 806 98.4 1.3 (0.8-2.1) 0.3
Yes 17 2 812 98
Acupuncture
No 649 1.6 40 578 98.4 3.1 (0.7-12.9) 0.3
Yes 2 4.8 40 95.2
Endoscopy
No 649 1.6 40 253 98.4 0.3 (0.1-1.4) 0.2
Yes 2 0.5 365 99.5
OR: Odds ratios, CI: confidence interval.
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lyzed according to gender, the prevalence was 2.29% and
0.93% in male and female subjects respectively. The differ-
ence was found to be statistically significant (P < 0.01), and
in all groups it showed higher prevalence in males than that
in females (Figure 2B). The males in age groups [30–39]
and [40–49] years represent the highest seroprevalence of
HBsAg found in this study (2.47% and 2.45% respectively).
Regarding the seropositivity of HBV and HCV dual in-
fection, the presence of both HBsAg and anti-HCV anti-
bodies was noted in 2 cases Out of 23 578 tested subjects.
These two patients were male subjects who belonged to
age groups 20–29 years and ≥50 years respectively.
Table 1 lists the frequency of potential risk factors
reported by subjects with positive and negative anti-
HCV results and the crude OR estimated by univariate
analysis. Factors significantly associated with HCV infec-
tion were increasing age, dental treatment, use of glass
syringes and surgical history. Conversely, no associationwas observed between HCV seropositivity and gender, re-
ceiving blood transfusion, tattooing, body piercing, having
multiple sexual partners, acupuncture and endoscopy. On
the subject of HBV infection, HBsAg positivity was signifi-
cantly associated with age, male gender (OR 2.5; p < 0.01),
Dental procedure history (OR 3.0; p < 0.01), Use of glass
syringes (OR 2.3; p < 0.01), history of jaundice (OR 1.4;
p = 0.03) and history of sexual risk behaviors (OR 2.9;
p < 0.01).
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A total of 169 605 voluntary blood donors were selected
in the Transfusion Blood Center of Casablanca between
January 2008 and December 2010 for the study, of whom
79.7% were males. The overall mean age was 35.7 (± 12.5)
years, ranging from 18 to 65 years. The seroprevalence
was estimated over the three-year study period. Among all
analyzed subjects, 1057 were anti-HCV positive, repre-
senting an overall prevalence of 0.62% (Table 2). The sero-
prevalence was 0.57% in 2008 but subsequently increased
to 0.64% in 2009 and 2010. Similarly, the prevalence of
HBV was slightly increased from 1.1% in 2008 to 1.15% in
2009 and decreased to 0.63% in 2010. The overall sero-
prevalence rate of HBV was 0.96% corresponding to 1603
HBsAg-positive individuals.
Discussion
We report here a cross-sectional study to assess the epi-
demiology of HCV and HBV prevalence among the general
population residing or working in the major Moroccan
regions and among blood donors from the Blood Transfu-
sion Center of Casablanca, the largest commercial and
densely populated city of Morocco. To the best of our
knowledge this is the largest community-based epidemio-
logic study of HCV and HBV infections from Morocco.
The sampling procedure adopted and the high participa-
tion rate (97.3%) support the absence of selection and non-
response bias, ensuring thus an accurate assessment of the
prevalence in our study. Most of the previous researchers
in this field were limited due to the selective nature of the
survey populations. The descriptive epidemiologic data
presented in this study can provide new insight into the
contribution of HCV and HBV in the etiology of liver dis-
ease in Morocco.
The overall prevalence of HCV infection in the general
population in our study is found to be 1.58% and was
lower than the prevalence reports from close countries;
Algeria (2.5%), Libya (3%) and Egypt (15%-20%) [10-12].
Our estimate was also too much lower compared to
what has been reported in the prior decade by Cacoub
et al. [13] in which the estimated HCV infection rate
was 7.7%. This result is surely related to the nature ofTable 2 The frequency of seropositivity of HBV and HCV
among blood donors at Blood Transfusion Center of
Casablanca 2008-2010
Year Total screened HCV positive HBV positive
N N (%) N (%)
2008 52 279 300 (0.57) 575 (1.1)
2009 55 496 357 (0.64) 638 (1.15)
2010 61 830 400 (0.64) 390 (0.63)
Total 169 605 1057 (0.62) 1603 (0.95)
N = Number.the participants enrolled in the study who were mostly
hospitalized patients and those who come for consult-
ation suffering from chronic hepatopathy or with
nephrological manifestations. Most HCV-seropositive
subjects in the present survey had detectable viremia
(70.9%), which is consistent with findings in studies from
France (80.6%) and Italy (75.9%) [14,15].
No statistically significant difference in HCV distribu-
tion according to gender was found in our study, which
is similar to other reports on community-acquired hepa-
titis C from United states and Belgium [16,17], However,
higher prevalence was observed in advanced age groups;
indeed, no anti-HCV seropositive case was found in 152
subjects in age groups younger than 20 years, neverthe-
less the seropositivity increased progressively from
adults (0.77%) to older persons (3.12%). This can be sup-
ported by two major reasons. First, before 1994, anti-
HCV screening among blood donors was not conducted
throughout Morocco and the association of blood trans-
fusion with HCV seropositivity should not be surprising
given that the blood product had not been previously
screened for HCV. Second, the higher prevalence of
HCV in older people could be attributed to a longer ex-
posure to risk factors for HCV transmission; for instance
iatrogenic transmission resulting from inadequately ste-
rilized equipments, inappropriate reuse of supplies, etc.
This risk factor is considered the main risk associated
with HCV infection in the majority of participants from
the general population included in this study. This same
risk is the primary cause for HCV transmission in many
outbreaks documented in United States and European
Union health care [18,19].
Regarding HBV infection, the overall prevalence of
HBsAg was significantly lower (1.81%) than that reported
from Algeria (3.6%) and Tunisia (4-7%) [20,21]. Despite the
large number of young in <20 group tested (152 subjects),
none was positive for HBsAg, These results indicate that
the strong efforts made among youngers have had some
success since the HBV infant vaccination was introduced in
1992 and integrated into the national immunization pro-
gram in 1999, in addition, hepatitis B immunoglobulin and
HBV vaccine treatment for newborns of HBV-infected
mothers at delivery could also contribute to the significant
reduction of vertical or perinatal transmission of HBV.
On the other hand, the age-related prevalence of HBsAg
showed a progressive decrease after 50 years (1.71%), so
among participants who were older than 50 years, the
prevalence of anti-HCV was higher (3.12%) than that of
HBsAg (1.71%). This can be probably due to deaths caused
by HBV-related cirrhosis and hepatocellular carcinoma in
this group [22]. Additionally, it has been reported that
HBV-associated HCC occurs approximately 10 years ear-
lier than HCV-associated HCC [23,24]. Conversely, on the
whole, the prevalence of HBV in our study population was
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the comparative incidence of the two viruses is consistent
with findings in studies conducted in India, China and
Bosnia-Herzegovina [3,5,25].
Analysis by gender reveals that, the seroprevalence of
hepatitis B among males is significantly higher than that
found in females; this data was comparable to other
reports [26], and no plausible explanation has been given
for the higher rate in males in the general population
but probably due to the higher exposure to occupational
HBV risk factors in men, or else females clear the HBV
more efficiently as compared to males [27].
Our research shows a very low prevalence (two cases
among 23 578 personts tested) of hepatitis co-infection
comparing with Tunisia (5%) and Egypt (22.5%) [28,29],
these results indicate that the HBV positive patients
investigated herein do not have an increased risk of ex-
posure to HCV infection. Although this small sample
size of reactive cases does not allow data to be compared
with other reports, one Italian study found that rates of
dual infection increased with age, and was more com-
mon in patients over 50 years of age [30]. In this report,
the two cases were male subjects belonging to age groups
20–29 years and ≥50 years respectively. Moreover several
authors have reported that HBV can reciprocally inhibit
HCV replication [31]; specifically, HBV DNA replication
has been shown to correlate with decreased HCV RNA
levels in coinfected patients [32]. In another Italian study,
coinfected patients had a rate of HCV RNA clearance of
71% compared to 14% with HCV monoinfection [31]. Fur-
thermore, coinfected patients have been demonstrated to
have lower levels of both HBV DNA and HCV RNA than
corresponding mono-infected controls, inicating that con-
current suppression of both viruses by the other virus can
also occur [33].
After all, according to research regarding HBV preva-
lence, Morocco has been estimated as a moderately en-
demic area; thus, in a WHO collaborative study on viral
hepatitis B in which 20 countries have participated, the
seroprevalence were reported was 3.3% [34]. Among bar-
bers and their customers, the positive ratio for HBsAg
was found to be 2.0% by Zahraoui et al. in 2004 and
28.0% by Belbacha et al. in 2011 [7,35]. Comparison of
these findings with the HBsAg carrier rate estimated in
this exhaustive investigation and our preliminary results
published by Sbai et al. [36], shows that the epidemio-
logical picture is changing and that the vaccination pro-
gram has shifted this trend to low endemicity.
In this study, we also measured over a period of three
years, the frequency of HCV and HBV infections among
169 605 voluntary blood donors assumed to be without
known or obvious risk factors. 0.62% and 0.96% of subjects
were tested positive for HCV antibodies and HBsAg re-
spectively, these results were significantly lower comparedwith the prevalence observed among the general popula-
tion reported here. This could be explained by the fact
that the volunteer blood donors are a preselected healthy
group based on donor questionnaires and physical exam-
ination as blood is drawn only from those applicants who
appear at low risk of having blood-borne pathogens [37].
Moreover, with regard to HCV infection, this prevalence
is considerably lower in comparison with that reported
among blood donors in 1998 at the same institution and
in 1992 at the Regional Blood Transfusion Center of Rabat
(0.70% and 1.56% respectively) [38]. This observation is
probably due to the improvement of the effectiveness of
the medical selection through self-exclusion from blood
donation and medical examination. When the results of
the present study were compared with those reported
from similar blood donors of other countries, a compar-
able prevalence of HCV antibodies has been reported in
blood donors from Libya (0.69%) and Germany (0.65%)
[39,40]. Studies from Tunisia (1.4 %), Senegal (0.8%) and
United States (1.8%) reported higher HCV infection rate
[41-43], whereas Algeria (0.18 %), Spain (0.3%), England
(0.1%), Bosnia and Herzegovina (0.27%) showed lower fre-
quency of the HCV antibodies seropositivity in compari-
son to the present study [20,44-46].
Measurement of HBV seropositivity, has revealed that
0.96% of the Moroccan blood donors had HBV infection.
This seroprevalence is lower than that reported in Algeria
(3.6%), Libya (1.28%), Turkey (1.8%) and Iran (1.07%)
[20,37,39,46]. Nevertheless, it is higher than the reactivity
rate reported in Rabat, Morocco (0.8%), a US community
(0.15%), and Bosnia-Herzegovina (0.78%) [8,25,47].
Conclusion
Our study throws light for the first time, on the current
epidemiological status of viral hepatitis B and C infections
in Morocco among the general population and blood
donors. This data shows that the prevalence of HBV and
HCV in blood donors was significantly lower than that
observed in the general population, which emphasizes that
the blood transfusion was not a contributing risk factor
for transmission of neither HBV nor HCV infection. The
main transmission route in Morocco is still attributed to
the nosocomial exposure to contaminated instruments.
The present survey reports that the HCV infection is
at an intermediate level of endemicity. It also underlines
the decrease of hepatitis B incidence rate compared with
previous studies. Even with a moderate prevalence, there
may be a large reservoir of HCV and HBV-infected per-
sons in Morocco, which indicates that many people are at
risk of developing chronic liver disease related to viral
hepatitis, added to the fact that antiviral therapy is not af-
fordable by the vast majority of people in developing
countries. Therefore, nosocomial risk prevention as well
as health education among population are the main
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